Stayble Therapeutics AB (publ)
SSTO:STABLShare Statistics
As of March 31, 2026, Stayble Therapeutics AB (publ) has 64.36M shares outstanding.
| Shares Outstanding | 64.36M |
Valuation Ratios
These figures are as of March 31, 2026.
| PB Ratio | 13.30 |
| P/TBV Ratio | -58.73 |
| P/FCF Ratio | -2.27 |
| P/OCF Ratio | -2.27 |
Financial Position
As of March 31, 2026, Stayble Therapeutics AB (publ) maintains a current ratio of 1.43, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.43 |
| Quick Ratio | 0.78 |
| Interest Coverage | -223.69 |
Financial Efficiency
Over the twelve months ended March 31, 2026, Stayble Therapeutics AB (publ) posted a negative return on equity (ROE) of -255.13, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -176.19, reflecting losses generated across the asset base.
| Return on Equity (ROE) | -255.13 |
| Return on Assets (ROA) | -176.19 |
Dividends & Yields
These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -44.15: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -31.52, meaning Stayble Therapeutics AB (publ) raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -31.52 |
| FCF Yield | -44.15 |
Stock Splits
Stayble Therapeutics AB (publ)'s most recent stock split took place on March 20, 2023 with a 1000:1027 split ratio.
| Last Split Date | 3/20/2023 |
| Split Ratio | 1000:1027 |
Scores
As of March 31, 2026, Stayble Therapeutics AB (publ) has an Altman Z-Score of -17.49, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -17.49 |